Medium materiality6/10
Guggenheim raises ArriVent Biopharma price target to $30 from $18
Why it may matterVerify against the original reporting
Bullish analyst view; the target implies substantial upside but is not a forecast guarantee.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raised its AVBP price target about 67% to $30; the posted price was $15.36, roughly 95% below the new target. This is a notable bullish analyst view, with substantial uncertainty inherent in a price target.
- Target raised from $18 to $30; posted price $15.36.
Key facts
- 01
Target: $30
- 02
Posted price: $15.36
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.